SCHEMBL14642

SCHEMBL14642

CN(c1ccc(F)cc1)[C@@H]1CCO[C@H]2CCCC[C@@]21O

nearest known ligand 0.55

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 8/20 0.55
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
SLC6A3 Q01959 2/20 0.32
ESR1 P03372 1/20 0.32
PGR P06401 1/20 0.32
HTR2A P28223 1/20 0.32
TRPC5 Q9UL62 1/20 0.32
POLB P06746 1/20 0.31
SLC6A2 P23975 1/20 0.31
SLC6A4 P31645 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11967090 1.00 TRPA1 (0.55) TRPA1DDB1CRBNSLC6A3ESR1
SCHEMBL11895279 0.90 TRPA1 (0.52) TRPA1DDB1CRBNPOLB
SCHEMBL2986 0.90 TRPA1 (0.52) TRPA1DDB1CRBNPOLB
SCHEMBL11967091 0.75 TRPA1 (0.55) TRPA1DDB1CRBNSLC6A3ESR1
SCHEMBL11954688 0.75 TRPA1 (0.55) TRPA1DDB1CRBNSLC6A3ESR1
SCHEMBL11895462 0.73 TRPA1 (0.45) TRPA1DDB1CRBNPOLB
SCHEMBL2932 0.72 TRPA1 (0.64) TRPA1SLC6A3ESR1PGRHTR2A
SCHEMBL11967350 0.72 TRPA1 (0.64) TRPA1SLC6A3ESR1PGRHTR2A
SCHEMBL14646 0.72 TRPA1 (0.64) TRPA1SLC6A3ESR1PGRHTR2A
SCHEMBL15827865 0.72 TRPA1 (0.64) TRPA1SLC6A3ESR1PGRHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2485737-B1 NOVEL TRPA1 ANTAGONISTS MERCK SHARP & DOHME (US) 2014-06-25 EP claimed
US-20120196894-A1 NOVEL TRPA1 ANTAGONISTS SCHERING CORPORATION 2012-08-02 US claimed
US-8829196-B2 TRPA1 antagonists MERCK SHARP & DOHME CORP. (US) 2014-09-09 US disclosed
US-8829196-B2 TRPA1 antagonists MERCK SHARP & DOHME CORP. (US) 2014-09-09 US disclosed
US-8829196-B2 TRPA1 antagonists MERCK SHARP & DOHME CORP. (US) 2014-09-09 US disclosed
EP-2485737-B1 NOVEL TRPA1 ANTAGONISTS MERCK SHARP & DOHME (US) 2014-06-25 EP disclosed
EP-2485737-B1 NOVEL TRPA1 ANTAGONISTS MERCK SHARP & DOHME (US) 2014-06-25 EP disclosed
US-20120196894-A1 NOVEL TRPA1 ANTAGONISTS SCHERING CORPORATION 2012-08-02 US disclosed
US-20120196894-A1 NOVEL TRPA1 ANTAGONISTS SCHERING CORPORATION 2012-08-02 US disclosed
US-20120196894-A1 NOVEL TRPA1 ANTAGONISTS SCHERING CORPORATION 2012-08-02 US disclosed
WO-2011043954-A1 NOVEL TRPA1 ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196894-A1 NOVEL TRPA1 ANTAGONISTS TRPA1, TRPV1, TRPV2 TRPA1 1/4885DDB1 2918/4885CRBN 4221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.